FindTrial
Sign In

Clinical application of autologous menstrual blood stromal stem cells combined with platelet-rich plasma transplantation on treating Asherman's syndrome

Mechanism research and clinical application of autologous MenSCs for endometrial regeneration

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16009068
Enrollment
Unknown
Registered
2016-08-23
Start date
2016-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asherman's syndrome

Interventions

MenSCs+PRP:autologous transplantation of MenSCs combined with PRP
MenSCs:autologous transplantation of MenSCs

Sponsors

Shengjing Hospital affiliated to China Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. aged 20-40 years; 2. infertility due to asherman's syndrome of women; 3. failed to regenerate the endometrium in other treatments such as hormonal therapy, intrauterine device, aspirin or traditional chinese medicine.

Exclusion criteria

Exclusion criteria: 1. acute urogenital infection; 2. combined with other genital disease ingcluding hysteromyoma, adenomyosis, hydrosalpinx or body disease that could not bear pregnancy.

Design outcomes

Primary

MeasureTime frame
endometrial thickness;endometrial morphology;subendometrial zone vascularity;pregnancy rate;—

Countries

China

Contacts

Public ContactJichun Tan

Shengjing Hospital affiliated to China Medical University

tjczjh@163.com+86 18940251868

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026